# Summit Therapeutics Inc.: overview

SMMT · Nasdaq · CIK 1599298 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/smmt.md) · [Financials](/companies/smmt/financials.md) · [Filings](/companies/smmt/filings.md) · [Insiders](/companies/smmt/insiders.md)

Latest reported revenue: [$0](/filings/0001599298-25-000048.md) for Q4 FY2024, three months to 2024-12-31, from the 10-K filed Feb 24, 2025 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001599298-25-000048).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.0](/filings/0001599298-24-000158.md) | [0.0 d](/filings/0001599298-25-000048.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.08)](/filings/0001599298-25-000159.md) | not reported | [(0.09)](/filings/0001599298-26-000039.md) | [(0.76)](/filings/0001599298-26-000068.md) | [(0.31)](/filings/0001599298-25-000159.md) | not reported | [(0.24)](/filings/0001599298-26-000039.md) | [(0.28)](/filings/0001599298-26-000068.md) |
| Free cash flow | $m | [(30.4) d](/filings/0001599298-25-000159.md) | [(48.7) d](/filings/0001599298-26-000015.md) | [(61.6)](/filings/0001599298-26-000039.md) | [(66.7) d](/filings/0001599298-26-000068.md) | [(93.2) d](/filings/0001599298-25-000159.md) | [(102) d](/filings/0001599298-26-000015.md) | [(123)](/filings/0001599298-26-000039.md) | [(142) d](/filings/0001599298-26-000068.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [1.8](/filings/0001599298-23-000034.md) | [0.7](/filings/0001599298-25-000048.md) | [0.0](/filings/0001599298-25-000048.md) | [0.0](/filings/0001599298-25-000048.md) | not reported |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(4764.3%)](/filings/0001599298-23-000034.md) | [(10225.4%)](/filings/0001599298-25-000048.md) | not reported | not reported | not reported |
| Net margin | % | [(4897.8%)](/filings/0001599298-23-000034.md) | [(11174.8%)](/filings/0001599298-25-000048.md) | not reported | not reported | not reported |
| Diluted EPS | $ per share | [(0.67)](/filings/0001599298-23-000034.md) | [(0.41)](/filings/0001599298-25-000048.md) | [(0.99)](/filings/0001599298-26-000015.md) | [(0.31)](/filings/0001599298-26-000015.md) | [(1.44)](/filings/0001599298-26-000015.md) |
| Free cash flow | $m | [(72.9)](/filings/0001599298-23-000034.md) | [(42.2)](/filings/0001599298-25-000048.md) | [(76.9)](/filings/0001599298-26-000015.md) | [(142)](/filings/0001599298-26-000015.md) | [(324)](/filings/0001599298-26-000015.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/smmt/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BAKER BROS. ADVISORS LP](/funds/1263508.md) | 2026-06-30 | $477.7m | 32,786,348 |  | Reduced −3,604,715 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $146.3m | 10,043,947 |  | Reduced −809,252 |
| [STATE STREET CORP](/funds/93751.md) | 2026-06-30 | $139.0m | 9,536,796 |  | Added +2,508,636 |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $138.8m | 9,529,041 |  | Reduced −124,717 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $83.6m | 5,734,484 |  | Added +22,682 |
| [UBS Group AG](/funds/1610520.md) | 2026-06-30 | $76.3m | 5,233,798 |  | Added +1,553,483 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $73.5m | 5,042,190 |  | Reduced −191,062 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $65.8m | 4,513,399 |  | Added +4,202,671 |
| [Point72 Asset Management, L.P.](/funds/1603466.md) | 2026-06-30 | $53.9m | 3,697,803 |  | Added +2,913,617 |
| [GEODE CAPITAL MANAGEMENT, LLC](/funds/1214717.md) | 2026-06-30 | $50.0m | 3,427,263 |  | Added +111,409 |

## Recent filings

[All 560 filings](/companies/smmt/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-10-19 | 11:01 ET | [DEF 14A](/filings/0001193125-26-424642.md) | Proxy statement, period 2026-11-04 | 0001193125-26-424642 |
| 2026-09-29 | 01:39 ET | [8-K](/filings/0001193125-26-405776.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.03 Amendment to articles or bylaws; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-405776 |
| 2026-09-15 | 12:44 ET | [8-K](/filings/0001599298-26-000081.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000081 |
| 2026-09-14 | 12:37 ET | [8-K](/filings/0001599298-26-000078.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000078 |
| 2026-09-03 | 13:21 ET | [8-K](/filings/0001599298-26-000076.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000076 |
| 2026-08-26 | 13:17 ET | [8-K](/filings/0001599298-26-000074.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000074 |
| 2026-08-05 | 11:32 ET | [8-K](/filings/0001599298-26-000071.md) | 8.01 Other events; 9.01 Financial statements and exhibits | 0001599298-26-000071 |
| 2026-07-23 | 20:34 ET | [8-K](/filings/0001193125-26-314214.md) | 1.01 Entry into a material agreement; 9.01 Financial statements and exhibits | 0001193125-26-314214 |
| 2026-07-23 | 20:08 ET | [10-Q](/filings/0001599298-26-000068.md) | Quarterly report, period 2026-06-30 | 0001599298-26-000068 |
| 2026-07-23 | 20:07 ET | [8-K](/filings/0001599298-26-000067.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001599298-26-000067 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001599298-26-000015.md), filed Feb 23, 2026.

## Forecast league

Not in this season’s league. [This season’s league](/leagues.md)

## About the filer

- CIK: 1599298
- Tickers: SMMT
- Exchange: Nasdaq
- SIC code: 2834 Pharmaceutical Preparations
- State of incorporation: not reported
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.